Chinese paraglider accidentally swept more than 28,000 ft above ground
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Chinese researchers test neural implant that lets amputee to move cursor with mind
China's state-owned broadcaster CCTV reported on Saturday that the country has become second only in the world to start human trials of its advanced invasive brain-computer interface (BCI) technology. The trial involves a 37-year-old man who lost all four limbs in a high-voltage electrical accident over ten years ago. In March, researchers implanted a coin-sized device and electrodes into his brain. Within weeks, the subject was able to control a cursor on a screen, allowing him to play chess, use a computer, and even game with near-normal skill, according to the CCTV report. Starting this year, the team will launch small-scale trials involving patients with paralysis or ALS, with plans to expand to as many as 40 participants by 2026. The effort is being led by the Chinese Academy of Sciences' (CAS) Centre for Excellence in Brain Science and Intelligence Technology, alongside Huashan Hospital at Fudan University in Shanghai and several industry partners, the South China Morning Post detailed. The deep brain stimulation electrode implanted in the patient is the smallest and most flexible of its kind in the world, Chinese media added. Created by the CAS research center, the electrode measures roughly 1/100th the width of a human hair and about one-fifth the thickness of Neuralink's electrodes, explained Zhao Zhengtao, a professor at the academy. Zhao also noted in a statement released by the CAS that the electrode's exceptional flexibility enables it to bend with the subtle movements of neurons sliding past one another. The design caused minimal disruption to surrounding tissue, with the patient's neurons barely affected by the implantation. Each electrode tip contains 32 sensors that capture brain signals, enabling long-term coexistence with brain tissue without triggering immune rejection. Before reaching human trials, the technology underwent extensive testing on mice and macaques to evaluate its safety, flexibility, and effectiveness. The implant measures 26mm (1 inch) in diameter and is 6mm thick. The implantation procedure took less than 30 minutes to complete. Surgeons thinned a coin-sized section of the skull above the motor cortex, creating a 5mm opening to insert the electrode. Before the operation, the surgical team used advanced scans to create a detailed 3D map of the patient's brain, allowing for precise planning. During the surgery, real-time navigation technology guided the team to place the electrode with millimeter-level accuracy, ensuring optimal positioning. In the coming months, the team will work closely with the patient to train him in controlling robotic arms, enabling him to perform practical tasks such as grasping and manipulating objects in everyday life. Future phases of the trial may involve more advanced tasks, such as steering complex devices like robotic dogs and embodied AI agents. Beyond its current use, the report emphasized that this technology holds promise for a range of medical applications and offers new treatment options for debilitating neurological disorders such as stroke, ALS, and Alzheimer's disease.
Yahoo
an hour ago
- Yahoo
Nantes make offer for South Korea international Hyun-seok Hong
FC Nantes have made an offer for South Korean international Hyun-seok Hong (26), according to Sky Sports Germany. The attacking midfielder currently plays for Mainz 05. Hong joined Mainz in August 2024 and has made 24 appearances for the Bundesliga club. Hong's current contract expires in 2028, having joined Mainz for a €4m fee. The report does not indicate the value of Nantes' initial offer. Advertisement Hong began his career in Germany at Unterhaching before moving to Austria with LASK. He then spent two years at Gent before earning a move to the German top flight. He has, however, struggled for game time since moving to Mainz, which has alerted potential suitors such as Nantes. Hyun-seok Hong has 14 senior caps for South Korea. He was also a member of the U23 South Korean squad that won gold at the Asian games – a victory that earned him exemption from mandatory military service. GFFN | Ed Marsh
Yahoo
4 hours ago
- Yahoo
China's NMPA approves initiation of InnoCare's trial of B7-H3 targeted ADC
The China National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE) has granted approval to the investigational new drug (IND) application of InnoCare Pharma to initiate a trial of ICP-B794, a B7-H3 targeted antibody-drug conjugate (ADC). This marks a step forward in the development of targeted therapies for solid tumours, including oesophageal, nasopharyngeal, lung, and prostate cancers, as well as head and neck squamous cell carcinomas, among others. The ADC is designed to deliver a potent payload through a protease-cleavable linker. This targeting mechanism is expected to decrease off-target effects and improve treatment outcomes for patients with solid tumours. According to InnoCare Pharma, there are currently no B7-H3-targeted therapies that have received marketing approval. This type I transmembrane protein is expressed highly in various solid tumours and is observed as a potential anti-tumour target. InnoCare Pharma CEO, chairwoman and co-founder Dr Jasmine Cui said: "ICP-B794 is developed from the company's proprietary ADC platform. The platform is designed to deliver ADCs with strong tumour-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes. 'As the platform continues to evolve, the company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology." InnoCare is focused on developing a drug portfolio targeting a wide range of solid tumour indications. The company's research and development (R&D) team discovers and develops platforms to address solid tumours. Their approach includes leveraging technologies to detect and progress potential drug candidates that could provide clinical advantages. Its ADC technology platform is complemented by precision medicine candidates like the tropomyosin receptor kinase (TRK) inhibitor zurletrectinib (ICP-723). In February 2025, the NMPA approved a Phase III trial of InnoCare Pharma's ICP-248 (Mesutoclax) with orelabrutinib as a first-line therapy for chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL). "China's NMPA approves initiation of InnoCare's trial of B7-H3 targeted ADC" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
